<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38457543</PMID><DateCompleted><Year>2024</Year><Month>03</Month><Day>11</Day></DateCompleted><DateRevised><Year>2024</Year><Month>05</Month><Day>06</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1536-5964</ISSN><JournalIssue CitedMedium="Internet"><Volume>103</Volume><Issue>10</Issue><PubDate><Year>2024</Year><Month>Mar</Month><Day>08</Day></PubDate></JournalIssue><Title>Medicine</Title><ISOAbbreviation>Medicine (Baltimore)</ISOAbbreviation></Journal><ArticleTitle>Coxsackie B virus-induced myocarditis in a patient with a history of lymphoma: A case report and review of literature.</ArticleTitle><Pagination><StartPage>e37248</StartPage><MedlinePgn>e37248</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e37248</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1097/MD.0000000000037248</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">In rare occasions, coxsackievirus infections can cause serious illness, such as encephalitis and myocarditis. The immunotherapies of cancer could increase the risk of myocarditis, especially when applying immune checkpoint inhibitors. Herein, we report a rare case of Coxsackie B virus-induced myocarditis in a patient with a history of lymphoma.</AbstractText><AbstractText Label="CASE PRESENTATION" NlmCategory="METHODS">A 32-year-old woman was admitted to the hospital with recurrent fever for more than 20 days, and she had a history of lymphoma. Before admission, the positron emission tomography/computed tomography result indicated that the patient had no tumor progression, and she was not considered the cancer-related fever upon arriving at our hospital. Patient's red blood cell, platelet count, and blood pressure were decreased. In addition, she had sinus bradycardia and 3 branch blocks, which was consistent with acute high lateral and anterior wall myocardial infarction. During hospitalization, the patient had recurrent arrhythmia, repeated sweating, poor mentation, dyspnea, and Coxsackie B virus were detected in patient's blood samples by pathogen-targeted next-generation sequencing. The creatine kinase, creatine kinase MB, and N-terminal pro-brain natriuretic peptide were persistently elevated. Consequently, the patient was diagnosed with viral myocarditis induced by Coxsackie B virus, and treated with acyclovir, gamma globulin combined with methylprednisolone shock therapy, trimetazidine, levosimendan, sildenan, continuous pump pressors with m-hydroxylamine, entecavir, adefovir, glutathione, pantoprazole, and low-molecular-weight heparin. Her symptoms worsened and died.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">We reported a case with a history of lymphoma presented with fever, myocardial injury, who was ultimately diagnosed with Coxsackie B virus-induced myocarditis. Moreover, pathogen-targeted next-generation sequencing indeed exhibited higher sensitivity compared to mNGS in detecting Coxsackie B virus.</AbstractText><CopyrightInformation>Copyright © 2024 the Author(s). Published by Wolters Kluwer Health, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Qian</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Critical Care Medicine, The Affiliated Hospital of Guizhou Medical University, Guiyang, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yuan</LastName><ForeName>Jia</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Critical Care Medicine, The Affiliated Hospital of Guizhou Medical University, Guiyang, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Wei</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Critical Care Medicine, The Affiliated Hospital of Guizhou Medical University, Guiyang, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ouyang</LastName><ForeName>Weiwei</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Oncology, The Affiliated Hospital of Guizhou Medical University and The Affiliated Cancer Hospital of Guizhou Medical University, Guiyang, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Bowen</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Critical Care Medicine, The Affiliated Hospital of Guizhou Medical University, Guiyang, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yehong</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Critical Care Medicine, The Affiliated Hospital of Guizhou Medical University, Guiyang, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tao</LastName><ForeName>Junling</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Critical Care Medicine, The Affiliated Hospital of Guizhou Medical University, Guiyang, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Xianjun</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Critical Care Medicine, The Affiliated Hospital of Guizhou Medical University, Guiyang, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Guangsu</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Critical Care Medicine, The Affiliated Hospital of Guizhou Medical University, Guiyang, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Zhendong</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Beijing Goldstandard Medicine Independent Clinical Laboratory Co. Ltd., Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Ying</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0009-0008-6405-5197</Identifier><AffiliationInfo><Affiliation>Department of Critical Care Medicine, The Affiliated Hospital of Guizhou Medical University, Guiyang, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Medicine (Baltimore)</MedlineTA><NlmUniqueID>2985248R</NlmUniqueID><ISSNLinking>0025-7974</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009205" MajorTopicYN="Y">Myocarditis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D029822" MajorTopicYN="N">Enterovirus B, Human</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003384" MajorTopicYN="Y">Coxsackievirus Infections</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014777" MajorTopicYN="Y">Virus Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005334" MajorTopicYN="N">Fever</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008223" MajorTopicYN="Y">Lymphoma</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors have no funding and conflicts of interest to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>3</Month><Day>11</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>3</Month><Day>8</Day><Hour>18</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>3</Month><Day>8</Day><Hour>14</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>3</Month><Day>8</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38457543</ArticleId><ArticleId IdType="pmc">PMC10919497</ArticleId><ArticleId IdType="doi">10.1097/MD.0000000000037248</ArticleId><ArticleId IdType="pii">00005792-202403080-00011</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bracamonte-Baran W, Cihakova D. Cardiac autoimmunity: myocarditis. Adv Exp Med Biol. 2017;1003:187–221.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5706653</ArticleId><ArticleId IdType="pubmed">28667560</ArticleId></ArticleIdList></Reference><Reference><Citation>Lampejo T, Durkin SM, Bhatt N, et al. . Acute myocarditis: aetiology, diagnosis and management. Clin Med (Lond). 2021;21:e505–10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8439515</ArticleId><ArticleId IdType="pubmed">34507935</ArticleId></ArticleIdList></Reference><Reference><Citation>Ammirati E, Frigerio M, Adler ED, et al. . Management of acute myocarditis and chronic inflammatory cardiomyopathy: an expert consensus document. Circ Heart Fail. 2020;13:e007405.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7673642</ArticleId><ArticleId IdType="pubmed">33176455</ArticleId></ArticleIdList></Reference><Reference><Citation>Imanaka-Yoshida K. Inflammation in myocardial disease: from myocarditis to dilated cardiomyopathy. Pathol Int. 2020;70:1–11.</Citation><ArticleIdList><ArticleId IdType="pubmed">31691489</ArticleId></ArticleIdList></Reference><Reference><Citation>Narovlyanskaya O, Winokur EJ. Viral myocarditis. Dimens Crit Care Nurs. 2020;39:75–80.</Citation><ArticleIdList><ArticleId IdType="pubmed">32000238</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson CM, Wang Y, Pfeiffer JK. Sex-dependent intestinal replication of an enteric virus. J Virol. 2017;91:e02101–16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5355612</ArticleId><ArticleId IdType="pubmed">28100612</ArticleId></ArticleIdList></Reference><Reference><Citation>Marjomaki V, Flodstrom-Tullberg M. Coxsackie B virus. Trends Microbiol. 2022;30:606–7.</Citation><ArticleIdList><ArticleId IdType="pubmed">35183399</ArticleId></ArticleIdList></Reference><Reference><Citation>Garmaroudi FS, Marchant D, Hendry R, et al. . Coxsackievirus B3 replication and pathogenesis. Future Microbiol. 2015;10:629–53.</Citation><ArticleIdList><ArticleId IdType="pubmed">25865198</ArticleId></ArticleIdList></Reference><Reference><Citation>Imanishi K, Tabuchi Y, Saitoh Y. [Immunohistochemical studies on colorectal adenoma and carcinoma—correlation of cellular dysplasia and intracellular CEA distribution, lectin-binding sites and quantities of nuclear Feulgen DNA content]. Nihon Geka Gakkai Zasshi. 1988;89:1632–40.</Citation><ArticleIdList><ArticleId IdType="pubmed">3200238</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang XM, Li YC, Chen P, et al. . MG-132 attenuates cardiac deterioration of viral myocarditis via AMPK pathway. Biomed Pharmacother. 2020;126:110091.</Citation><ArticleIdList><ArticleId IdType="pubmed">32278272</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao D, Hu Y, Jiang X, et al. . Applying the pathogen-targeted next-generation sequencing method to pathogen identification in cerebrospinal fluid. Ann Transl Med. 2021;9:1675.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8667110</ArticleId><ArticleId IdType="pubmed">34988184</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonaca MP, Olenchock BA, Salem JE, et al. . Myocarditis in the setting of cancer therapeutics: proposed case definitions for emerging clinical syndromes in cardio-oncology. Circulation. 2019;140:80–91.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6779326</ArticleId><ArticleId IdType="pubmed">31390169</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson DB, Balko JM, Compton ML, et al. . Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med. 2016;375:1749–55.</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359:1350–5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7391259</ArticleId><ArticleId IdType="pubmed">29567705</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang DY, Johnson DB, Davis EJ. Toxicities associated with PD-1/PD-L1 blockade. Cancer J. 2018;24:36–40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5784852</ArticleId><ArticleId IdType="pubmed">29360726</ArticleId></ArticleIdList></Reference><Reference><Citation>Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378:158–68.</Citation><ArticleIdList><ArticleId IdType="pubmed">29320654</ArticleId></ArticleIdList></Reference><Reference><Citation>Cameron BJ, Gerry AB, Dukes J, et al. . Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells. Sci Transl Med. 2013;5:197ra–03.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6002776</ArticleId><ArticleId IdType="pubmed">23926201</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan YK, Liu YP. Magnetic resonance imaging features of pediatric coxsackievirus encephalitis. J Belg Soc Radiol. 2019;103:6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6328711</ArticleId><ArticleId IdType="pubmed">30637372</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu W, Miller S, Chiu CY. Clinical metagenomic next-generation sequencing for pathogen detection. Annu Rev Pathol. 2019;14:319–38.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6345613</ArticleId><ArticleId IdType="pubmed">30355154</ArticleId></ArticleIdList></Reference><Reference><Citation>Li F, Wang Y, Zhang Y, et al. . Etiology of severe pneumonia in children in alveolar lavage fluid using a high-throughput gene targeted amplicon sequencing assay. Front Pediatr. 2021;9:659164.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8267249</ArticleId><ArticleId IdType="pubmed">34249808</ArticleId></ArticleIdList></Reference><Reference><Citation>Valestra PK, Fornos SH, Gian J, et al. . Coxsackie B5 infection in an adult with fever, truncal rash, diarrhea and splenomegaly with highly elevated ferritin levels. IDCases. 2016;6:14–6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5011156</ArticleId><ArticleId IdType="pubmed">27617209</ArticleId></ArticleIdList></Reference><Reference><Citation>Brunetti L, DeSantis ER. Treatment of viral myocarditis caused by coxsackievirus B. Am J Health Syst Pharm. 2008;65:132–7.</Citation><ArticleIdList><ArticleId IdType="pubmed">18192257</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Q, MacDonald NE, Smith JC, et al. . Severe enterovirus type 71 nervous system infections in children in the Shanghai region of China: clinical manifestations and implications for prevention and care. Pediatr Infect Dis J. 2014;33:482–7.</Citation><ArticleIdList><ArticleId IdType="pubmed">24732390</ArticleId></ArticleIdList></Reference><Reference><Citation>Teng S, Wei Y, Zhao SY, et al. . Intestinal detoxification time of hand-foot-and-mouth disease in children with EV71 infection and the related factors. World J Pediatr. 2015;11:380–5.</Citation><ArticleIdList><ArticleId IdType="pubmed">26454441</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang G, Wang J, Yao G, et al. . Efficacy of high-dose methylprednisolone pulse therapy in the treatment of enterovirus 71 encephalitis. Pak J Pharm Sci. 2016;29(4 Suppl):1421–7.</Citation><ArticleIdList><ArticleId IdType="pubmed">27592493</ArticleId></ArticleIdList></Reference><Reference><Citation>Ammirati E, Bizzi E, Veronese G, et al. . Immunomodulating therapies in acute myocarditis and recurrent/acute pericarditis. Front Med (Lausanne). 2022;9:838564.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8958011</ArticleId><ArticleId IdType="pubmed">35350578</ArticleId></ArticleIdList></Reference><Reference><Citation>Shu H, Peng Y, Hang W, et al. . Trimetazidine in heart failure. Front Pharmacol. 2020;11:569132.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7883591</ArticleId><ArticleId IdType="pubmed">33597865</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu K, Deng D, Yu B, et al. . Evaluation of the efficacy and safety of Chinese herbal injection combined with trimetazidine for viral myocarditis: a network meta-analysis. Front Pharmacol. 2021;12:630896.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8117092</ArticleId><ArticleId IdType="pubmed">33995029</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu S, Chang G, Gao L, et al. . Trimetazidine protects against myocardial ischemia/reperfusion injury by inhibiting excessive autophagy. J Mol Med (Berl). 2018;96:791–806.</Citation><ArticleIdList><ArticleId IdType="pubmed">29955901</ArticleId></ArticleIdList></Reference><Reference><Citation>Rivadeneyra L, Charo N, Kviatcovsky D, et al. . Role of neutrophils in CVB3 infection and viral myocarditis. J Mol Cell Cardiol. 2018;125:149–61.</Citation><ArticleIdList><ArticleId IdType="pubmed">30393107</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>